Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of [11C]T-1650 PET Radioligand
NCT03861000Phase 2Completed
- Sponsor
- National Institute of Mental Health
- Start
- Mar 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 11C-T-1650 (3 arms), sponsored by National Institute of Mental Health. Primary endpoints: Whole Brain Total Distribution Volume at 120 minutes and Standard Uptake Value Area Under the Curve. Started Mar 2019; status: completed.
02
Drugs
11C-T-1650
Beyond the preview
Go deeper on NCT03861000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861000.